LNTH vs. QDEL, NEOG, RIOT, CLDX, NTLA, MYGN, OGN, BBIO, HALO, and IONS
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include QuidelOrtho (QDEL), Neogen (NEOG), Riot Platforms (RIOT), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS).
Lantheus (NASDAQ:LNTH) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
Lantheus currently has a consensus target price of $99.17, indicating a potential upside of 24.47%. QuidelOrtho has a consensus target price of $59.00, indicating a potential upside of 37.79%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than Lantheus.
QuidelOrtho received 112 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.28% of users gave QuidelOrtho an outperform vote while only 65.21% of users gave Lantheus an outperform vote.
Lantheus has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.
In the previous week, QuidelOrtho had 5 more articles in the media than Lantheus. MarketBeat recorded 16 mentions for QuidelOrtho and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.75 beat QuidelOrtho's score of 0.07 indicating that Lantheus is being referred to more favorably in the media.
Lantheus has a net margin of 33.72% compared to QuidelOrtho's net margin of -61.65%. Lantheus' return on equity of 54.10% beat QuidelOrtho's return on equity.
99.1% of Lantheus shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 1.0% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Lantheus has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats QuidelOrtho on 13 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
